News & Events

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that positive, updated data from its phase 2/3 clinical trial study of omacetaxine in chronic myeloid leukemia (CML) patients with resistance to multiple tyrosine kinase inhibitors (TKIs) was presented at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany on Saturday....

> Read More

ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion overnight at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation....

> Read More

ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the completion of its 1 for 14 nonrenounceable rights issue at A$0.43 per share, raising the maximum A$7.4 million. The rights issue was fully subscribed with demand being greater than the 17,122,453 shares available under the rights issue. The company has completed an A$1 million placement (2,325,580 shares at A$0.43 per share) to a small number of institutional investors to partially satisfy the strong demand and reduce the amount of scale-back required for the rights issue top-up facility....

> Read More

ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today that new data from two clinical studies and one pre-clinical study with omacetaxine will be presented at oral sessions during the forthcoming 14th Congress of the European Hematology Association (EHA) in Berlin, Germany....

> Read More

A treatment for skin ailments, based on a common weed, has moved closer to commercialisation with the release yesterday of trial data on clearing sunspots...

> Read More

SKIN treatment specialist Peplin has reported "positive" results from a late-stage clinical trial of its gel to treat pre-cancerous sun spots...

> Read More

> Read More

> Read More

> Read More

> Read More

Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, theâ?¦

> Read More

> Read More

Biotechnology company Hatchtech Pty Ltd today announced that Paul MacLeman has resigned as Chief Executive Officer and Director. The company congratulates Dr MacLeman who is leaving to take up the CEO role at a high profile publicly listed biotechnology company. Since…

> Read More

Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies announced today that The Ohio State University Medical Center in Columbus, Ohio has successfully completed the first two implants of the Company's C-PulseTM heart assist system under aâ?¦

> Read More

> Read More

-- New Data Published in Leukemia Showed 90% Kill of Leukemic Stem Cells and Prolonged Survival in Mice with Resistant CML - Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are…

> Read More

Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, theâ?¦

> Read More

Dear Arana Shareholder, I am writing to you to ensure you are up to date with several important developments for Arana Therapeutics Limited ("Arana"). As you may already be aware, on 27 February 2009 Cephalon, Inc. (Nasdaq: CEPH) announced that its wholly-ownedâ?¦

> Read More

Cephalon, Inc. (Nasdaq: CEPH) today announced that its wholly-owned subsidary, Cephalon International Holdings, Inc., intends to make a cash takeover offer for all of the shares in Arana Therapeutics Limited which it does not already own (ASX: AAH) ("Arana") at a minimum price of $1.40 per…

> Read More

CogState Ltd (ASX:CGS) and United BioSource Corporation (UBC) announced today that they will not renew the strategic relationship the two companies initiated in 2008 to co-market and co-deliver CogState's ClinicalTrials software for computerized cognitive testing in clinical trials. …

> Read More

Met primary efficacy endpoint with statistically significant complete clearance rate of AK lesions vs. vehicle Reduction in overall lesion count in all active treatment groups Well-tolerated, rapidly resolving local skin responses at all concentrations and durations …

> Read More

Xenome Limited ("Xenome") today announced it has executed a research licence agreement with MedImmune LLC (MedImmune"), a wholly owned subsidiary of AstraZeneca. Under the partnership MedImmune will gain access to Xenome's xdiscoverT venom peptide library to exclusively…

> Read More

Plantronics Discovery 925 beats competitors from Jawbone, BlueAnt and Motorola in an independent consumer research study performed by 7B Labs. 7B Labs announced today that the Plantronics Discovery 925 has won its Premium Bluetooth Headset Challenge, beating out the Aliph…

> Read More

Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the appointment of Michael M. Kitt, M.D., to the position of Chief Medical Officer. "Dr. Kitt is an…

> Read More

Sunshine Heart (ASX: SHC) announces the retirement of Malcolm McComas as a director of the Company effective 16 December 2008. Mr McComas was chairman of Sunshine Heart, Inc. from its listing on the ASX in September 2004 until its last annual general meeting on 30 Octoberâ?¦

> Read More